Navigation Links
Afid Therapeutics Inc.'s New Anticoagulant Heparin Replacement Passes in Vivo Test

LANSING, Mich., Aug. 19 /PRNewswire/ -- Afid Therapeutics, Inc. announced today that it had completed successful in vitro and in vivo (whole animal) demonstrations of the efficacy of its new "traceless" anticoagulant, which is meant to replace heparin in many applications. The in vivo and some of the in vitro studies were carried out by an independent certified third party laboratory. Heparin is a complex drug, which is used beyond the reach of chemical synthesis and can only be obtained from sources such as the intestines and lungs of pigs and cattle. The manufacture and use of heparin from cattle is banned in the US, Canada and Europe, and the main commercial sources of heparin used in North America and Europe are in China where it is purified from the intestines of pigs. There is a very high degree of variability in activity and preparations are prone to contamination.

Heparin is one of the most widely used drugs. Its many uses include the treatment of acute deep venous thrombosis and pulmonary embolism. It is also used to prevent the occurrence of venous thromboembolism in some patients. Two other important other uses of heparin are as adjuncts in dialysis to prevent clotting and to prevent intravascular coagulation during open heart surgical procedures. Heparin is also used to treat angina and to prevent clotting in i.v. devices. Problems in the use of heparin include bleeding in about 10% of patients and the induction of hypersentivity and osteoporosis. There is an intense effort aimed at finding a replacement for heparin.

The new Afid Therapeutics anticoagulant mimics heparin and is designed to produce only carbohydrates and amino acids when it degrades in the blood stream thus minimizing the risks of side effects. Cell toxicity studies carried out thus far show no effect on the viability of mammalian cells.

"We are very appreciative of the support we have received from these organizations. This has been critical to our success," said Rawle Hollingsworth President and Founder of Afid Therapeutics. "We are preparing for the filing of an NDA in the near future."

Afid Therapeutics Inc. specializes in advanced chemistry based on carbohydrates with a focus on the drug discovery and development areas. In addition to its internal R&D efforts in drug discovery and development, Afid Therapeutics provides advanced chemical intermediates to over 80 pharmaceutical companies and research entities around the world. The company has received critical funding from the MEDC 21st Century Fund, Corn Marketing Program of Michigan, the Ann Arbor Spark and the Western Michigan Biosciences Research Commercialization Center.

The Afid Therapeutics chemistry platform is based on the conversion of plant materials, especially from corn and sugar beet, into advanced drugs and other chemical intermediates.

SOURCE Afid Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Prime Therapeutics Receives TIPPS Certification
2. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
3. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
4. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
5. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
6. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
7. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
8. Prime Therapeutics Announces URAC Accreditation
9. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
10. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
11. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
Post Your Comments:
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, ... Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility ... home to some of the world’s leading providers of cereal and other breakfast foods. ...
(Date:6/26/2016)... Charlotte, NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind ... able to be personalized through a fitness app. The fitness app plans to fix the ... solutions currently only offer a one size fits all type program , They ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Austin residents ... the American College of Mohs Surgery and to Dr. Russell Peckham for medical and ... highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the ... Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , “We ... new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/24/2016)... Calif. , June 24, 2016  Global ... a biopharmaceutical company developing novel therapeutics for the ... needs, today announced the closing of its previously ... common stock, at the public offering price of ... the offering were offered by GBT. GBT estimates ...
(Date:6/24/2016)... 2016 Dehaier Medical Systems Ltd. (NASDAQ: ... markets and sells medical devices and wearable sleep respiratory ... strategic cooperation agreement with Hongyuan Supply Chain Management Co., ... June 20, 2016, to develop Dehaier,s new Internet medical ... Dehaier will leverage Hongyuan Supply Chain,s sales platform to ...
Breaking Medicine Technology: